Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Apr;111(4):1073–1080. doi: 10.1111/j.1476-5381.1994.tb14854.x

Behavioural and neurochemical adaptations to nicotine in rats: influence of NMDA antagonists.

M Shoaib 1, M E Benwell 1, M T Akbar 1, I P Stolerman 1, D J Balfour 1
PMCID: PMC1910130  PMID: 8032593

Abstract

1. The repeated co-administration of the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine (0.1 and 0.3 mg kg-1, i.p.) with nicotine (0.4 mg kg-1, s.c.) attenuated the development of tolerance to the locomotor depressant effect of the nicotine in rats. 2. The repeated co-administration of the competitive NMDA antagonist D-CPPene (SDZ EAA 494; 3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid, 2 and 8 mg kg-1, i.p.) also attenuated tolerance to the locomotor depressant effect of nicotine. 3. Dizocilpine (0.3 mg kg-1, i.p.) pretreatment attenuated sensitization to the locomotor stimulant effect of nicotine (0.4 mg kg-1, s.c.) and prevented sensitization of nicotine-induced dopamine release in the nucleus accumbens. However, pretreatment with dizocilpine alone caused a modest enhancement of the behavioural response to a subsequent acute dose of nicotine. 4. D-CPPene (2.0 mg kg-1, i.p.) pretreatment prevented sensitization to the nicotine-induced dopamine release in the nucleus accumbens. There was no enhanced locomotor response that could be attributed to nicotine pretreatment when D-CPPene was co-administered with nicotine. However, pretreatment with D-CPPene alone enhanced the locomotor response to an acute dose of nicotine. 5. The results suggest the involvement of NMDA receptors in adaptations of the behavioural and neurochemical effects of nicotine that occur as a result of repeated administration of the drug.

Full text

PDF
1073

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amador M., Dani J. A. MK-801 inhibition of nicotinic acetylcholine receptor channels. Synapse. 1991 Mar;7(3):207–215. doi: 10.1002/syn.890070305. [DOI] [PubMed] [Google Scholar]
  2. Ben-Eliyahu S., Marek P., Vaccarino A. L., Mogil J. S., Sternberg W. F., Liebeskind J. C. The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res. 1992 Mar 20;575(2):304–308. doi: 10.1016/0006-8993(92)90094-p. [DOI] [PubMed] [Google Scholar]
  3. Benwell M. E., Balfour D. J. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol. 1992 Apr;105(4):849–856. doi: 10.1111/j.1476-5381.1992.tb09067.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Caggiula A. R., Epstein L. H., Antelman S. M., Saylor S. S., Perkins K. A., Knopf S., Stiller R. Conditioned tolerance to the anorectic and corticosterone-elevating effects of nicotine. Pharmacol Biochem Behav. 1991 Sep;40(1):53–59. doi: 10.1016/0091-3057(91)90319-w. [DOI] [PubMed] [Google Scholar]
  5. Clarke P. B., Fu D. S., Jakubovic A., Fibiger H. C. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther. 1988 Aug;246(2):701–708. [PubMed] [Google Scholar]
  6. Clarke P. B., Kumar R. The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br J Pharmacol. 1983 Feb;78(2):329–337. doi: 10.1111/j.1476-5381.1983.tb09398.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clarke P. B., Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res. 1985 Dec 2;348(2):355–358. doi: 10.1016/0006-8993(85)90456-1. [DOI] [PubMed] [Google Scholar]
  8. Fallon J. H., Moore R. Y. Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J Comp Neurol. 1978 Aug 1;180(3):545–580. doi: 10.1002/cne.901800310. [DOI] [PubMed] [Google Scholar]
  9. Hendry J. S., Rosecrans J. A. The development of pharmacological tolerance to the effect of nicotine on schedule-controlled responding in mice. Psychopharmacology (Berl) 1982;77(4):339–343. doi: 10.1007/BF00432767. [DOI] [PubMed] [Google Scholar]
  10. Huettner J. E., Bean B. P. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1307–1311. doi: 10.1073/pnas.85.4.1307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Imperato A., Mulas A., Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol. 1986 Dec 16;132(2-3):337–338. doi: 10.1016/0014-2999(86)90629-1. [DOI] [PubMed] [Google Scholar]
  12. Karler R., Calder L. D., Chaudhry I. A., Turkanis S. A. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sci. 1989;45(7):599–606. doi: 10.1016/0024-3205(89)90045-3. [DOI] [PubMed] [Google Scholar]
  13. Karler R., Chaudhry I. A., Calder L. D., Turkanis S. A. Amphetamine behavioral sensitization and the excitatory amino acids. Brain Res. 1990 Dec 24;537(1-2):76–82. doi: 10.1016/0006-8993(90)90341-8. [DOI] [PubMed] [Google Scholar]
  14. Ksir C., Hakan R. L., Kellar K. J. Chronic nicotine and locomotor activity: influences of exposure dose and test dose. Psychopharmacology (Berl) 1987;92(1):25–29. doi: 10.1007/BF00215474. [DOI] [PubMed] [Google Scholar]
  15. Kuribara H., Asami T., Ida I., Iijima Y., Tadokoro S. Effects of repeated MK-801 on ambulation in mice and in sensitization following methamphetamine. Psychopharmacology (Berl) 1992;108(3):271–275. doi: 10.1007/BF02245111. [DOI] [PubMed] [Google Scholar]
  16. Mariathasan E.A., Stolerman I.P. Discrimination of agonist-antagonist mixtures: experiments with nicotine plus mecamylamine. Behav Pharmacol. 1993 Dec;4(6):555–561. [PubMed] [Google Scholar]
  17. Marks M. J., Stitzel J. A., Collins A. C. Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther. 1985 Dec;235(3):619–628. [PubMed] [Google Scholar]
  18. Morrisett R. A., Rezvani A. H., Overstreet D., Janowsky D. S., Wilson W. A., Swartzwelder H. S. MK-801 potently inhibits alcohol withdrawal seizures in rats. Eur J Pharmacol. 1990 Jan 25;176(1):103–105. doi: 10.1016/0014-2999(90)90138-v. [DOI] [PubMed] [Google Scholar]
  19. Morrison C. F., Stephenson J. A. The occurrence of tolerance to a central depressant effect of nicotine. Br J Pharmacol. 1972 Sep;46(1):151–156. doi: 10.1111/j.1476-5381.1972.tb06857.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pauly J. R., Grun E. U., Collins A. C. Tolerance to nicotine following chronic treatment by injections: a potential role for corticosterone. Psychopharmacology (Berl) 1992;108(1-2):33–39. doi: 10.1007/BF02245282. [DOI] [PubMed] [Google Scholar]
  21. Ramoa A. S., Alkondon M., Aracava Y., Irons J., Lunt G. G., Deshpande S. S., Wonnacott S., Aronstam R. S., Albuquerque E. X. The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. J Pharmacol Exp Ther. 1990 Jul;254(1):71–82. [PubMed] [Google Scholar]
  22. Reavill C., Stolerman I. P. Locomotor activity in rats after administration of nicotinic agonists intracerebrally. Br J Pharmacol. 1990 Feb;99(2):273–278. doi: 10.1111/j.1476-5381.1990.tb14693.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Schenk S., Valadez A., McNamara C., House D. T., Higley D., Bankson M. G., Gibbs S., Horger B. A. Development and expression of sensitization to cocaine's reinforcing properties: role of NMDA receptors. Psychopharmacology (Berl) 1993;111(3):332–338. doi: 10.1007/BF02244949. [DOI] [PubMed] [Google Scholar]
  24. Schwartz R. D., Kellar K. J. In vivo regulation of [3H]acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J Neurochem. 1985 Aug;45(2):427–433. doi: 10.1111/j.1471-4159.1985.tb04005.x. [DOI] [PubMed] [Google Scholar]
  25. Shoaib M., Stolerman I. P. MK801 attenuates behavioural adaptation to chronic nicotine administration in rats. Br J Pharmacol. 1992 Mar;105(3):514–515. doi: 10.1111/j.1476-5381.1992.tb09010.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stewart J., Druhan J. P. Development of both conditioning and sensitization of the behavioral activating effects of amphetamine is blocked by the non-competitive NMDA receptor antagonist, MK-801. Psychopharmacology (Berl) 1993;110(1-2):125–132. doi: 10.1007/BF02246961. [DOI] [PubMed] [Google Scholar]
  27. Stolerman I. P., Bunker P., Jarvik M. E. Nicotine tolerance in rats; role of dose and dose interval. Psychopharmacologia. 1974 Feb 6;34(4):317–324. doi: 10.1007/BF00422555. [DOI] [PubMed] [Google Scholar]
  28. Trujillo K. A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 1991 Jan 4;251(4989):85–87. doi: 10.1126/science.1824728. [DOI] [PubMed] [Google Scholar]
  29. Vale A. L., Balfour D. J. Aversive environmental stimuli as a factor in the psychostimulant response to nicotine. Pharmacol Biochem Behav. 1989 Apr;32(4):857–860. doi: 10.1016/0091-3057(89)90048-8. [DOI] [PubMed] [Google Scholar]
  30. Weihmuller F. B., O'Dell S. J., Cole B. N., Marshall J. F. MK-801 attenuates the dopamine-releasing but not the behavioral effects of methamphetamine: an in vivo microdialysis study. Brain Res. 1991 May 24;549(2):230–235. doi: 10.1016/0006-8993(91)90462-5. [DOI] [PubMed] [Google Scholar]
  31. Welzl H., Bättig K., Berz S. Acute effects of nicotine injection into the nucleus accumbens on locomotor activity in nicotine-naive and nicotine-tolerant rats. Pharmacol Biochem Behav. 1990 Dec;37(4):743–746. doi: 10.1016/0091-3057(90)90557-x. [DOI] [PubMed] [Google Scholar]
  32. Wise R. A., Bozarth M. A. A psychomotor stimulant theory of addiction. Psychol Rev. 1987 Oct;94(4):469–492. [PubMed] [Google Scholar]
  33. Wolf M. E., Khansa M. R. Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res. 1991 Oct 18;562(1):164–168. doi: 10.1016/0006-8993(91)91202-c. [DOI] [PubMed] [Google Scholar]
  34. Wong E. H., Kemp J. A., Priestley T., Knight A. R., Woodruff G. N., Iversen L. L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci U S A. 1986 Sep;83(18):7104–7108. doi: 10.1073/pnas.83.18.7104. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES